Liang, Jin-Hua <br/><br/>
Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial.  [electronic resource] 

 -  Haematologica  01 2020 
 - e29-e32 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2019.220301  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Cyclophosphamide<br/>Doxorubicin<br/>Etoposide<br/>Humans<br/>Lymphohistiocytosis, Hemophagocytic--diagnosis<br/>Lymphoma, Non-Hodgkin--complications<br/>Prednisone<br/>Vincristine--adverse effects